By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Multi User License - $2,999
Coming Soon
The pharmaceutical sector differs due to a number of peculiar traits. It is also a contradictory industry, despite the undeniable fact that for more than a century the industry has made a significant contribution to human well being and the reduction of illness and suffering, it continues to consistently rank among the least trusted industries in public opinion polls,
frequently being negatively compared to the nuclear industry. Even though it is unquestionably one of the riskiest industries to invest in, the public thinks it is one of the most profitable.
The US pharmaceuticals market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
An agreement to sell shares to Pfizer was made by clinical-stage biopharmaceutical business Zentalis Pharmaceuticals, Inc., which specialises in finding and developing small molecule medicines that target the core molecular pathways of malignancies.
A registered direct offering without an underwriter or placement agent was used to offer and sell the common shares to Pfizer. The net proceeds from the offering will be put to use by Zentalis for working capital and other general corporate reasons, as well as for clinical trials that are already underway or that are slated to begin soon, such as those using the Wee1 inhibitor ZN-c3 and the BCL-2 inhibitor ZN-d5.
The National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), numerous bio-pharmaceutical and life science companies, non-profits, and other organisations have joined forces to create the Accelerating Medicines Partnership (AMP) programme, which aims to change the way new diagnostics and treatments are developed.
The AMP partners’ shared objective is to speed up and lower the cost of developing innovative diagnostics and treatments for patients.
The NIH and AMP partners are sharing knowledge and resources through this cross-sector partnership, which is overseen by the Foundation for the NIH (FNIH), as well as in-kind contributions in an integrated governance structure that enables the best-informed contributions to science from all participants.
